Science

Splash's lead clinical candidate is SPL-108 which targets CD44. SPL-108 has demonstrated strong activity in numerous cancer animal models and has completed multiple Phase I and II clinical studies in around 100 subjects. SPL-108 demonstrated single agent activity (doubling of progression free survival) and an excellent safety profile in some of those clinical trials.

SPL-108 in combination with paclitaxel is currently being tested in a clinical trial in platinum-resistant ovarian cancer patients.